Alkermes plc Stock
Alkermes plc Stock
Alkermes plc shows a slight decrease today, losing -€0.190 (-0.440%) compared to yesterday.
The stock is one of the favorites of our community with 23 Buy predictions and 1 Sell predictions.
As a result the target price of 46 € shows a slightly positive potential of 7.91% compared to the current price of 42.63 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -0.440% | 0.448% | -9.586% | 86.974% | 80.636% | 67.835% | 76.157% |
| Icon plc | 0.570% | 0.317% | -1.693% | 4.517% | -8.164% | -38.901% | - |
| United Therapeutics | -0.580% | 3.809% | -3.937% | 79.784% | 9.057% | 115.741% | 156.044% |
| Ligand Pharmaceuticals | -3.820% | -0.781% | -9.286% | 117.094% | 53.012% | 313.008% | 171.194% |
Comments
Alkermes (ALKS) had its "overweight" rating reaffirmed by Piper Sandler.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Earnings Call Highlights
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes reported strong Q2 performance: Revenue reached $496 million, while proprietary product sales rose 34% year
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes’ lead orexin agonist, alixorexton, has entered Phase 3 with the Brilliance program now enrolling in